{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:10:07Z","timestamp":1778285407736,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"the Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["#18K15915"],"award-info":[{"award-number":["#18K15915"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4913-5","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T09:10:00Z","timestamp":1539940200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9266-3658","authenticated-orcid":false,"given":"Taizou","family":"Hirano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"koarai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,19]]},"reference":[{"issue":"10072","key":"4913_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","volume":"389","author":"JC Soria","year":"2017","unstructured":"Soria JC, Tan DS, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomized, open-label, phase 3 study. Lancet. 2017;389(10072):917\u201329.","journal-title":"Lancet"},{"issue":"4","key":"4913_CR2","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","volume":"17","author":"DW Kim","year":"2016","unstructured":"Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicenter, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452\u201363.","journal-title":"Lancet Oncol"},{"issue":"24","key":"4913_CR3","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","volume":"34","author":"L Crin\u00f2","year":"2016","unstructured":"Crin\u00f2 L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866\u201373.","journal-title":"J Clin Oncol"},{"key":"4913_CR4","doi-asserted-by":"crossref","unstructured":"Felip E, Orlov S, Park K, et al. Phase 2 study of ceritinib in ALKi-na\u00efve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): whole body responses in the overall pts group and in pts with baseline brain metastases (BM). Ann Oncol. 2016;27(6) Meeting Abstract: 1208O. \n                    https:\/\/academic.oup.com\/annonc\/article\/27\/suppl_6\/1208O\/2800066\n                    \n                  .","DOI":"10.1093\/annonc\/mdw383.03"},{"issue":"7","key":"4913_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","volume":"18","author":"AT Shaw","year":"2017","unstructured":"Shaw AT, Kim TM, Crin\u00f2 L, et al. ASCEND-5: a randomized, phase3 study of ceritinib versus chemotherapy in adult patients with ALK-rearranged non-small cell lung cancer, previously treated with chemotherapy and crizotinib. Lancet Oncol. 2017;18(7):874\u201386.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4913_CR6","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.jtho.2017.04.006","volume":"12","author":"T Hirano","year":"2017","unstructured":"Hirano T, Yamada M, Ichinose M. Chronic cholestasis with dilation of intrahepatic bile duct related to Administration of Ceritinib. J Thorac Oncol. 2017;12(8):e123\u20135.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4913_CR7","first-page":"225","volume":"17","author":"D Boraschi","year":"2006","unstructured":"Boraschi D, Dinarello C. IL-18 in autimmunity: review. Eur Cytokine Netw. 2006;17(4):225\u201352.","journal-title":"Eur Cytokine Netw"},{"issue":"2","key":"4913_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1046\/j.1365-2249.2000.01356.x","volume":"122","author":"T Yamamoto","year":"2000","unstructured":"Yamamoto T, Higashi T, Nouso K, et al. Serum interferon-gamma-inducing factor\/IL-18 levels in primary biliary cirrhosis. Clin Exp Immunol. 2000;122(2):227\u201331.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"4913_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.15252\/emmm.201506154","volume":"8","author":"T Hirano","year":"2016","unstructured":"Hirano T, Kikuchi T, Tode N, et al. OX40 ligand newly expressed on bronchiolar progenitors mediates influenza infection and further exacerbates pneumonia. EMBO Mol Med. 2016;8(4):422\u201336.","journal-title":"EMBO Mol Med"},{"key":"4913_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.lungcan.2017.06.004","volume":"111","author":"C Raffaele","year":"2017","unstructured":"Raffaele C, Alastair G, Rohit L, et al. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. Lung Cancer. 2017;111:51\u20138.","journal-title":"Lung Cancer"},{"key":"4913_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002371-200203001-00013","volume":"25","author":"M Hirota","year":"2002","unstructured":"Hirota M, Shibata M, Ogawa M. Increased plasma concentrations of interleukin-18 in patients with hepatic failure 1 week after surgery. J Immunother. 2002;25:75\u20137.","journal-title":"J Immunother"},{"key":"4913_CR12","first-page":"246","volume":"49","author":"W Naumnik","year":"2004","unstructured":"Naumnik W, Chyczewska E, Kovalchuk O, et al. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Rocz Akad Med Bialymst. 2004;49:246\u201351.","journal-title":"Rocz Akad Med Bialymst"},{"issue":"6","key":"4913_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1023\/A:1020600230977","volume":"22","author":"O Ludwiczek","year":"2002","unstructured":"Ludwiczek O, Kaser A, Novick D, et al. Plasma levels of interleukin-18 and interleukin18 binding protein are elevated in patients with chronic liver disease. J Clin Immnol. 2002;22(6):331\u20137.","journal-title":"J Clin Immnol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4913-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4913-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4913-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T13:30:05Z","timestamp":1589463005000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4913-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,19]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4913"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4913-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,19]]},"assertion":[{"value":"28 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for reporting this case was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written, informed consent was obtained from the patient for publication of this case report and all accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"995"}}